http://wiki.ihe.net/api.php?action=feedcontributions&user=Stephane.spahni&feedformat=atomIHE Wiki - User contributions [en]2024-03-29T15:32:30ZUser contributionsMediaWiki 1.35.5http://wiki.ihe.net/index.php?title=Pharm_Meeting_Minutes_2021.03.17&diff=124526Pharm Meeting Minutes 2021.03.172021-03-17T14:06:40Z<p>Stephane.spahni: /* Participants */</p>
<hr />
<div>= Meeting details =<br />
<br />
<br />
==''' Location '''==<br />
<br />
::Session 1 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk0MDVlM2EtYWMyMy00MTZiLTlmMzktMjlkZGUxOWUzZTAw%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
:: Session 2 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGFjMDU0YTAtOTM4Mi00N2VkLTg2MTgtMDhjZjg5M2E3ODVk%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
<br />
= '''Minutes''' =<br />
<br />
== Q1 13:00- 14:30 Change proposals & Medication Lists ==<br />
<br />
* Participants:<br />
** Leonidas Tzimis<br />
** Stephane Spahni<br />
** Jose Costa Teixeira<br />
** Michael Tan<br />
** Jurgen Brandstatter<br />
** Jacqueline Surugue<br />
<br />
<br />
===Change Proposals ===<br />
<br />
* Switzerland has recently organized a projectathon. A third projectathon is planned. This includes CDA and FHIR profiles.<br />
<br />
Overview: [https://drive.google.com/file/d/1d4TiC2h7qRiS7oEZVDNU2soQULycZyhQ/view?usp=sharing CP Overview]<br />
<br />
:* [https://drive.google.com/file/d/1-48FLRY3BEnJuZ_nyz0Bfq1kFiOgWPYI/view?usp=sharing CP-PHARM-142] Proofreading / clarifications on CMPD, MTP, PADV profiles<br />
:** Fixes something we have forgotten when we introduced COMMENT. <br />
:** there are 2 definitions on XDS DocumentEntryType as a parameter.<br />
<br />
:* [https://drive.google.com/file/d/1WdPatA8OYpkD3uk0g1OeBHOrR-lfqBho/view?usp=sharing CP-PHARM-143] Align definitions of doseQuantity & rateQuantity (PRE profile)<br />
:** Dose and rate quantity is herited from PCC. Is it a quantity or a range. Which unit is allowed.There is a difference with PCC definition. <br />
:* [https://drive.google.com/file/d/1hzA_L9iXVIy3sMWqzWHsJdSgMphGLy7G/view?usp=sharing CP-PHARM-144] Forbid the use of ContextConductionInd (CMPD, MTP, PRE, DIS, PADV profiles)<br />
:** Context conduction code. Relationships are inherited along to addtional attributes. There has been a lot of discussion within HL7. Proposed to discourage the use of context conduction <br />
:* [https://drive.google.com/file/d/1Yc4_QX9MaSEvYhNHE6gS5Hc3mJFUeOTE/view?usp=sharing CP-PHARM-145] Cross-community PHARM-1 (CMPD profile)<br />
:** A patient could live in another community. Need to forward the information to another community. Can reuse ITI38 and ITI18, but patient ID must be known. <br />
:* [https://drive.google.com/file/d/1kko76AnrwaramEwPsHovwj6veCNgT6td/view?usp=sharing CP-PHARM-146] New MHD-based transaction PHARM-5 (CMPD profile)<br />
:** Need to support also RESTbased concepts which is then PHARM-5. Do we need to position it as a new approach to CMPD and not as temporarily solution? Is this a Swiss solution or an International approach? Jose is in a favor to keep low profile. <br />
:** 3 possible solutions. <br />
<br />
:* [https://drive.google.com/file/d/1ejY288pLJOJVhVZkQmmvPklkDYGvxwgi/view?usp=sharing CP-PHARM-147] moodCode for patient-reported medications (MTP, PRE, DIS, PADV, CMA profiles)<br />
:** In case a patient reports medication then it should be a event as mood code. In other cases it will be INT, whcih stands for intent.<br />
:* [https://drive.google.com/file/d/1m41hAFgwzLys6nmlibP-vg9IrbUJ5Ioi/view?usp=sharing OID Tree]<br />
:** Decide to leave the errors unchanged. Too much risk because of referenced chapters.<br />
For information only:<br />
:* [https://drive.google.com/file/d/1QwnGshWO9LYXLAZ9BY2-unaLBMbbZ4sL/view?usp=sharing CP-ITI-xxx] "RegistryStoredQueryResponse_Message" versus "RegistryStoredQuery_Response_Message" spelling<br />
:* [https://drive.google.com/file/d/1VcJBTO8JJh1winqBmOqmZVj7ghv9MPg6/view?usp=sharing CP-PCC-xxx] Order of approachSiteCode, doseQuantity and rateQuantity varies --> may impact IHE PRE & MTP profiles<br />
<br />
=== Medication lists ===<br />
<br />
* In Belgium there is understanding that there are different needs for a medication list.<br />
* We cannot force one formula for a medication list.<br />
* The patient records accumulates all the information from different resources.<br />
* Medication as a grouping item. It is more like a drill down mechanism.<br />
<br />
== 14:30- 15:00 Break ==<br />
<br />
== Q2 15:00- 16:30 Vaccination Topics ==<br />
<br />
=== Participants ===<br />
<br />
* Michael Tan<br />
* Jose Costa Teixeira<br />
* Jurgen Brandstaetter<br />
* Leonidas Tzimis<br />
* Jacqueline Surugue<br />
* Marc Robberecht<br />
* Stéphane Spahni<br />
<br />
== Work items ==<br />
<br />
* Review Doc from Chriss Carr [https://docs.google.com/document/d/1kb4U4Yr7m4rJ34vOnezqs5nRKGYyBzPVnrNl-KECQtI/edit?ts=6050cc04 work item]<br />
<br />
== Logical Model ==<br />
<br />
* WHO model<br />
* European Model<br />
* Belgian Model<br />
* German Model<br />
<br />
* The IHE Pharmacy material can be found here:<br />
https://github.com/IHE/pharm-vaccination<br />
: and <br />
<br />
http://build.fhir.org/ig/IHE/pharm-vaccination/branches/master/StructureDefinition-ihe-pharm-vaccination.html<br />
<br />
* the WHO FHIR material can be found in Github.<br />
<br />
https://github.com/who-int/svc<br />
<br />
https://github.com/gcangioli/vaccineCertificate<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Minutes]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Meeting_Agenda_2021.03.17&diff=124462Pharm Meeting Agenda 2021.03.172021-03-15T07:43:44Z<p>Stephane.spahni: /* Change Proposals */</p>
<hr />
<div>= Meeting details =<br />
<br />
<br />
==''' Location '''==<br />
<br />
::Session 1 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk0MDVlM2EtYWMyMy00MTZiLTlmMzktMjlkZGUxOWUzZTAw%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
:: Session 2 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGFjMDU0YTAtOTM4Mi00N2VkLTg2MTgtMDhjZjg5M2E3ODVk%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
<br />
= '''Agenda''' =<br />
<br />
== Q1 13:00- 14:30 Change proposals & Medication Lists ==<br />
<br />
===Change Proposals ===<br />
<br />
Overview: [https://drive.google.com/file/d/1d4TiC2h7qRiS7oEZVDNU2soQULycZyhQ/view?usp=sharing CP Overview]<br />
<br />
:* [https://drive.google.com/file/d/1-48FLRY3BEnJuZ_nyz0Bfq1kFiOgWPYI/view?usp=sharing CP-PHARM-142] Proofreading / clarifications on CMPD, MTP, PADV profiles<br />
:* [https://drive.google.com/file/d/1WdPatA8OYpkD3uk0g1OeBHOrR-lfqBho/view?usp=sharing CP-PHARM-143] Align definitions of doseQuantity & rateQuantity (PRE profile)<br />
:* [https://drive.google.com/file/d/1hzA_L9iXVIy3sMWqzWHsJdSgMphGLy7G/view?usp=sharing CP-PHARM-144] Forbid the use of ContextConductionInd (CMPD, MTP, PRE, DIS, PADV profiles)<br />
:* [https://drive.google.com/file/d/1Yc4_QX9MaSEvYhNHE6gS5Hc3mJFUeOTE/view?usp=sharing CP-PHARM-145] Cross-community PHARM-1 (CMPD profile)<br />
:* [https://drive.google.com/file/d/1kko76AnrwaramEwPsHovwj6veCNgT6td/view?usp=sharing CP-PHARM-146] New MHD-based transaction PHARM-5 (CMPD profile)<br />
:* [https://drive.google.com/file/d/1ejY288pLJOJVhVZkQmmvPklkDYGvxwgi/view?usp=sharing CP-PHARM-147] moodCode for patient-reported medications (MTP, PRE, DIS, PADV, CMA profiles)<br />
:* [https://drive.google.com/file/d/1m41hAFgwzLys6nmlibP-vg9IrbUJ5Ioi/view?usp=sharing OID Tree]<br />
<br />
For information only:<br />
:* [https://drive.google.com/file/d/1QwnGshWO9LYXLAZ9BY2-unaLBMbbZ4sL/view?usp=sharing CP-ITI-xxx] "RegistryStoredQueryResponse_Message" versus "RegistryStoredQuery_Response_Message" spelling<br />
:* [https://drive.google.com/file/d/1VcJBTO8JJh1winqBmOqmZVj7ghv9MPg6/view?usp=sharing CP-PCC-xxx] Order of approachSiteCode, doseQuantity and rateQuantity varies --> may impact IHE PRE & MTP profiles<br />
<br />
=== Medication lists ===<br />
<br />
== 14:30- 15:00 Break ==<br />
<br />
== Q2 15:00- 16:30 Vaccination Topics ==<br />
<br />
<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Meeting_Agenda_2021.03.17&diff=124461Pharm Meeting Agenda 2021.03.172021-03-15T07:42:24Z<p>Stephane.spahni: /* Change Proposals */</p>
<hr />
<div>= Meeting details =<br />
<br />
<br />
==''' Location '''==<br />
<br />
::Session 1 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk0MDVlM2EtYWMyMy00MTZiLTlmMzktMjlkZGUxOWUzZTAw%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
:: Session 2 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGFjMDU0YTAtOTM4Mi00N2VkLTg2MTgtMDhjZjg5M2E3ODVk%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
<br />
= '''Agenda''' =<br />
<br />
== Q1 13:00- 14:30 Change proposals & Medication Lists ==<br />
<br />
===Change Proposals ===<br />
:* [https://drive.google.com/file/d/1-48FLRY3BEnJuZ_nyz0Bfq1kFiOgWPYI/view?usp=sharing CP-PHARM-142] Proofreading / clarifications on CMPD, MTP, PADV profiles<br />
:* [https://drive.google.com/file/d/1WdPatA8OYpkD3uk0g1OeBHOrR-lfqBho/view?usp=sharing CP-PHARM-143] Align definitions of doseQuantity & rateQuantity (PRE profile)<br />
:* [https://drive.google.com/file/d/1hzA_L9iXVIy3sMWqzWHsJdSgMphGLy7G/view?usp=sharing CP-PHARM-144] Forbid the use of ContextConductionInd (CMPD, MTP, PRE, DIS, PADV profiles)<br />
:* [https://drive.google.com/file/d/1Yc4_QX9MaSEvYhNHE6gS5Hc3mJFUeOTE/view?usp=sharing CP-PHARM-145] Cross-community PHARM-1 (CMPD profile)<br />
:* [https://drive.google.com/file/d/1kko76AnrwaramEwPsHovwj6veCNgT6td/view?usp=sharing CP-PHARM-146] New MHD-based transaction PHARM-5 (CMPD profile)<br />
:* [https://drive.google.com/file/d/1ejY288pLJOJVhVZkQmmvPklkDYGvxwgi/view?usp=sharing CP-PHARM-147] moodCode for patient-reported medications (MTP, PRE, DIS, PADV, CMA profiles)<br />
<br />
For information only:<br />
:* [https://drive.google.com/file/d/1QwnGshWO9LYXLAZ9BY2-unaLBMbbZ4sL/view?usp=sharing CP-ITI-xxx] "RegistryStoredQueryResponse_Message" versus "RegistryStoredQuery_Response_Message" spelling<br />
:* [https://drive.google.com/file/d/1VcJBTO8JJh1winqBmOqmZVj7ghv9MPg6/view?usp=sharing CP-PCC-xxx] Order of approachSiteCode, doseQuantity and rateQuantity varies --> may impact IHE PRE & MTP profiles<br />
<br />
=== Medication lists ===<br />
<br />
== 14:30- 15:00 Break ==<br />
<br />
== Q2 15:00- 16:30 Vaccination Topics ==<br />
<br />
<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Meeting_Agenda_2021.03.17&diff=124460Pharm Meeting Agenda 2021.03.172021-03-15T07:39:31Z<p>Stephane.spahni: /* Q1 13:00- 14:30 Change proposals & Medication Lists */</p>
<hr />
<div>= Meeting details =<br />
<br />
<br />
==''' Location '''==<br />
<br />
::Session 1 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk0MDVlM2EtYWMyMy00MTZiLTlmMzktMjlkZGUxOWUzZTAw%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
:: Session 2 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGFjMDU0YTAtOTM4Mi00N2VkLTg2MTgtMDhjZjg5M2E3ODVk%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
<br />
= '''Agenda''' =<br />
<br />
== Q1 13:00- 14:30 Change proposals & Medication Lists ==<br />
<br />
===Change Proposals ===<br />
:* [https://drive.google.com/file/d/1-48FLRY3BEnJuZ_nyz0Bfq1kFiOgWPYI/view?usp=sharing CP-PHARM-142] Proofreading / clarifications on CMPD, MTP, PADV profiles<br />
:* CP-PHARM-143 Align definitions of doseQuantity & rateQuantity (PRE profile)<br />
:* CP-PHARM-144 Forbid the use of ContextConductionInd (CMPD, MTP, PRE, DIS, PADV profiles)<br />
:* CP-PHARM-145 Cross-community PHARM-1 (CMPD profile)<br />
:* CP-PHARM-146 New MHD-based transaction PHARM-5 (CMPD profile)<br />
:* CP-PHARM-147 moodCode for patient-reported medications (MTP, PRE, DIS, PADV, CMA profiles)<br />
<br />
For information only:<br />
:* CP-ITI-xxx "RegistryStoredQueryResponse_Message" versus "RegistryStoredQuery_Response_Message" spelling<br />
:* CP-PCC-xxx Order of approachSiteCode, doseQuantity and rateQuantity varies --> may impact IHE PRE & MTP profiles<br />
<br />
=== Medication lists ===<br />
<br />
== 14:30- 15:00 Break ==<br />
<br />
== Q2 15:00- 16:30 Vaccination Topics ==<br />
<br />
<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Meeting_Agenda_2021.03.17&diff=124435Pharm Meeting Agenda 2021.03.172021-03-11T16:12:35Z<p>Stephane.spahni: /* Change Proposals */</p>
<hr />
<div>= Meeting details =<br />
<br />
<br />
==''' Location '''==<br />
<br />
::Session 1 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk0MDVlM2EtYWMyMy00MTZiLTlmMzktMjlkZGUxOWUzZTAw%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
:: Session 2 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGFjMDU0YTAtOTM4Mi00N2VkLTg2MTgtMDhjZjg5M2E3ODVk%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
<br />
= '''Agenda''' =<br />
<br />
== Q1 13:00- 14:30 Change proposals & Medication Lists ==<br />
<br />
===Change Proposals ===<br />
:* CP-PHARM-142 Proofreading / clarifications on CMPD, MTP, PADV profiles<br />
:* CP-PHARM-143 Align definitions of doseQuantity & rateQuantity (PRE profile)<br />
:* CP-PHARM-144 Forbid the use of ContextConductionInd (CMPD, MTP, PRE, DIS, PADV profiles)<br />
:* CP-PHARM-145 Cross-community PHARM-1 (CMPD profile)<br />
:* CP-PHARM-146 New MHD-based transaction PHARM-5 (CMPD profile)<br />
:* CP-PHARM-147 moodCode for patient-reported medications (MTP, PRE, DIS, PADV, CMA profiles)<br />
<br />
For information only:<br />
:* CP-ITI-xxx "RegistryStoredQueryResponse_Message" versus "RegistryStoredQuery_Response_Message" spelling<br />
:* CP-PCC-xxx Order of approachSiteCode, doseQuantity and rateQuantity varies --> may impact IHE PRE & MTP profiles<br />
<br />
=== Medication lists ===<br />
<br />
<br />
== 14:30- 15:00 Break ==<br />
<br />
== Q2 15:00- 16:30 Vaccination Topics ==<br />
<br />
<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Meeting_Agenda_2021.03.17&diff=124427Pharm Meeting Agenda 2021.03.172021-03-10T13:52:19Z<p>Stephane.spahni: /* Change Proposals */</p>
<hr />
<div>= Meeting details =<br />
<br />
<br />
==''' Location '''==<br />
<br />
::Session 1 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk0MDVlM2EtYWMyMy00MTZiLTlmMzktMjlkZGUxOWUzZTAw%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
:: Session 2 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGFjMDU0YTAtOTM4Mi00N2VkLTg2MTgtMDhjZjg5M2E3ODVk%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
<br />
= '''Agenda''' =<br />
<br />
== Q1 13:00- 14:30 Change proposals & Medication Lists ==<br />
<br />
===Change Proposals ===<br />
:* CP-PHARM-142 Proofreading / clarifications on CMPD, MTP, PADV profiles<br />
:* CP-PHARM-143 Align definitions of doseQuantity & rateQuantity (PRE profile)<br />
:* CP-PHARM-144 Forbid the use of ContextConductionInd (CMPD, MTP, PRE, DIS, PADV profiles)<br />
:* CP-PHARM-145 Cross-community PHARM-1 (CMPD profile)<br />
:* CP-PHARM-146 New MHD-based transaction PHARM-5 (CMPD profile)<br />
:* CP-PHARM-147 moodCode for patient-reported medications (MTP profile)<br />
<br />
For information only:<br />
:* CP-ITI-xxx "RegistryStoredQueryResponse_Message" versus "RegistryStoredQuery_Response_Message" spelling<br />
:* CP-PCC-xxx Order of approachSiteCode, doseQuantity and rateQuantity varies --> may impact IHE PRE & MTP profiles<br />
<br />
=== Medication lists ===<br />
<br />
<br />
== 14:30- 15:00 Break ==<br />
<br />
== Q2 15:00- 16:30 Vaccination Topics ==<br />
<br />
<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Meeting_Agenda_2021.03.17&diff=124426Pharm Meeting Agenda 2021.03.172021-03-10T13:49:22Z<p>Stephane.spahni: /* Change Proposals */</p>
<hr />
<div>= Meeting details =<br />
<br />
<br />
==''' Location '''==<br />
<br />
::Session 1 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTk0MDVlM2EtYWMyMy00MTZiLTlmMzktMjlkZGUxOWUzZTAw%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
:: Session 2 Login for [https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGFjMDU0YTAtOTM4Mi00N2VkLTg2MTgtMDhjZjg5M2E3ODVk%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Teams]<br />
<br />
= '''Agenda''' =<br />
<br />
== Q1 13:00- 14:30 Change proposals & Medication Lists ==<br />
<br />
===Change Proposals ===<br />
:* CP-PHARM-142 Proofreading / clarifications on CMPD, MTP, PADV profiles<br />
:* CP-PHARM-143 Align definitions of doseQuantity & rateQuantity (PRE profile)<br />
:* CP-PHARM-144 Forbid the use of ContextConductionInd (CMPD, MTP, PRE, DIS, PADV profiles)<br />
:* CP-PHARM-145 Cross-community PHARM-1 (CMPD profile)<br />
:* CP-PHARM-146 New MHD-based transaction PHARM-5 (CMPD profile)<br />
:* CP-PHARM-147 moodCode for patient-reported medications (MTP profile)<br />
<br />
=== Medication lists ===<br />
<br />
<br />
== 14:30- 15:00 Break ==<br />
<br />
== Q2 15:00- 16:30 Vaccination Topics ==<br />
<br />
<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Plan_Minutes_2020.10.02&diff=122900Pharm Plan Minutes 2020.10.022020-10-07T06:01:30Z<p>Stephane.spahni: /* Medication lists */</p>
<hr />
<div>= Minutes =<br />
<br />
== Welcome ==<br />
* Participants<br />
** Stephane Spahni<br />
** Jose Costa Teixeira<br />
** Leonidas Tzimis<br />
** Esther Peelen<br />
** Michael Tan (scribe)<br />
<br />
<br />
* Review and Approve Agenda<br />
* Minutes previous meetings:<br />
<br />
https://wiki.ihe.net/index.php/Pharm_Tech_Minutes_2020.09.04<br />
<br />
* minutes approved and action items checked<br />
<br />
= Work Item Proposals 2020- 2021 =<br />
<br />
== Supply ==<br />
<br />
*This will be the main work item for the period 2020-2021<br />
** The team has been working on a logical ( abstract) model. These are represented in FHIR resources.<br />
** One of the logical models is an inventory report. This could lead to new FHIR resource.<br />
** FHIR resources have been proposed to HL7 ( O&O).<br />
** One important issue is which FHIR resource to use to represent a product. There are multiple solutions.<br />
** This problem has been escalated to the JIC ( joint initiative council).<br />
** The directors will come with a proposal for the approach of this issue.<br />
** Esther has discussed this topic with Christian Hay and he has introduced Marco Schwarzenbach from the GDSN.(This is a network to exchange product information.)<br />
<br />
* The FHIR implementation guide is pending on this issue being solved. There is already a draft for the implemenation guide. <br />
* Target date for the planning is July 2021. <br />
* The implementation guide will cover the 3 transactions. Normally HL7 does not cover the workflow in their IG, but this is an essential element in an IHE profile. Therefore IHE Pharmacy will add the workflow processes into the FHIR IG. <br />
<br />
== Vaccinations == <br />
* Belgium will be working on an IHE profile on vaccinations. This profile is for the Child Health services for pediatrics. However the vaccinations are not restricted only to children. It is especially under attention because of the Corona crisis. <br />
* Netherlands is also extending their vaccination program to provide data to patients in their Personal Healthcare Environment. (PHR). This will also be using FHIR resources to feed the PHR's. This program has just recently started.<br />
* Switzerland has also a project on vaccinations. A central (national) system do exists. An exports of the current vaccinations is being implemented based on a CDA document (standardized at national level - CDA-CH-VACD).<br />
<br />
== Medication lists ==<br />
<br />
* The medication list will generate maintenance activities. There will be change proposals for the maintenance. <br />
* One new transaction has to be introduced, which will be Pharm-5. This will be the biggest part of the work. This will be almost like Pharm-1, but will be using HMD instead of XDS. <br />
* Switzerland has had a projectathon where medication list was the focus (modification of a medication list through PADV and MTP documents).<br />
* We need to clear up the models of CDA and FHIR. <br />
* Gazelle tools need to be able to validate FHIR as well as CDA. <br />
* The EPR should support both standards. The target is to go live mid 2021 in certain Cantons, for example Geneva.<br />
* Plan it for the October session and also invite Olier Egger. '''action Michael'''<br />
<br />
* Jose mentions that Belgium is also picking up a Medication list. He has advised them to look into IHE Pharmacy Medication lists.<br />
<br />
= Planning Meeting = <br />
<br />
== F2F meetings ==<br />
<br />
* Autumn F2F 22-23 October.<br />
** Michael has set up the initial agenda. Please review the proposed agenda.<br />
* IHE World Summit is postponed.<br />
** national events are taking place F2F.<br />
** connectathon is virtual.<br />
** General assembly may be mixed. Planned for Friday 6 november. To be confirmed.<br />
** webinars are also being considered.<br />
<br />
== Any other business ==<br />
<br />
<br />
* The next Technical committee meeting might collide with the general assembly. Need to check later on.<br />
* GS1 healthcare conference is planned 17-19 November. This takes place twice a year. Esther will send a link. '''action Esther'''<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Minutes]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Plan_Minutes_2020.10.02&diff=122899Pharm Plan Minutes 2020.10.022020-10-07T06:00:39Z<p>Stephane.spahni: /* Vaccinations */</p>
<hr />
<div>= Minutes =<br />
<br />
== Welcome ==<br />
* Participants<br />
** Stephane Spahni<br />
** Jose Costa Teixeira<br />
** Leonidas Tzimis<br />
** Esther Peelen<br />
** Michael Tan (scribe)<br />
<br />
<br />
* Review and Approve Agenda<br />
* Minutes previous meetings:<br />
<br />
https://wiki.ihe.net/index.php/Pharm_Tech_Minutes_2020.09.04<br />
<br />
* minutes approved and action items checked<br />
<br />
= Work Item Proposals 2020- 2021 =<br />
<br />
== Supply ==<br />
<br />
*This will be the main work item for the period 2020-2021<br />
** The team has been working on a logical ( abstract) model. These are represented in FHIR resources.<br />
** One of the logical models is an inventory report. This could lead to new FHIR resource.<br />
** FHIR resources have been proposed to HL7 ( O&O).<br />
** One important issue is which FHIR resource to use to represent a product. There are multiple solutions.<br />
** This problem has been escalated to the JIC ( joint initiative council).<br />
** The directors will come with a proposal for the approach of this issue.<br />
** Esther has discussed this topic with Christian Hay and he has introduced Marco Schwarzenbach from the GDSN.(This is a network to exchange product information.)<br />
<br />
* The FHIR implementation guide is pending on this issue being solved. There is already a draft for the implemenation guide. <br />
* Target date for the planning is July 2021. <br />
* The implementation guide will cover the 3 transactions. Normally HL7 does not cover the workflow in their IG, but this is an essential element in an IHE profile. Therefore IHE Pharmacy will add the workflow processes into the FHIR IG. <br />
<br />
== Vaccinations == <br />
* Belgium will be working on an IHE profile on vaccinations. This profile is for the Child Health services for pediatrics. However the vaccinations are not restricted only to children. It is especially under attention because of the Corona crisis. <br />
* Netherlands is also extending their vaccination program to provide data to patients in their Personal Healthcare Environment. (PHR). This will also be using FHIR resources to feed the PHR's. This program has just recently started.<br />
* Switzerland has also a project on vaccinations. A central (national) system do exists. An exports of the current vaccinations is being implemented based on a CDA document (standardized at national level - CDA-CH-VACD).<br />
<br />
== Medication lists ==<br />
<br />
* The medication list will generate maintenance activities. There will be change proposals for the maintenance. <br />
* One new transaction has to be introduced, which will be Pharm-5. This will be the biggest part of the work. This will be almost like Pharm-1, but will be using HMD instead of XDS. <br />
* Switserland has had a projectathon where medication list will be the focus.<br />
* We need to clear up the models of CDA and FHIR. <br />
* Gazelle tools need to be able to validate FHIR as well as CDA. <br />
* The EPR should support both standards. The target is to go live mid 2021 in certain Cantons, for example Geneva.<br />
* Plan it for the October session and also invite Olier Egger. '''action Michael'''<br />
<br />
* Jose mentions that Belgium is also picking up a Medication list. He has advised them to look into IHE Pharmacy Medication lists.<br />
<br />
= Planning Meeting = <br />
<br />
== F2F meetings ==<br />
<br />
* Autumn F2F 22-23 October.<br />
** Michael has set up the initial agenda. Please review the proposed agenda.<br />
* IHE World Summit is postponed.<br />
** national events are taking place F2F.<br />
** connectathon is virtual.<br />
** General assembly may be mixed. Planned for Friday 6 november. To be confirmed.<br />
** webinars are also being considered.<br />
<br />
== Any other business ==<br />
<br />
<br />
* The next Technical committee meeting might collide with the general assembly. Need to check later on.<br />
* GS1 healthcare conference is planned 17-19 November. This takes place twice a year. Esther will send a link. '''action Esther'''<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Minutes]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2020.04.23&diff=120932Pharm Tech Minutes 2020.04.232020-04-24T07:07:19Z<p>Stephane.spahni: /* Medication lists */</p>
<hr />
<div>= Minutes =<br />
<br />
: Link to Microsoft Teams [https://teams.microsoft.com/l/meetup-join/19%3ameeting_YTFlMWQyMTEtMmVhZi00MTUwLTgyM2ItYTk1OTkzNmEyNjhi%40thread.v2/0?context=%7b%22Tid%22%3a%223d542e8d-a3eb-448f-998d-dd6880dc119c%22%2c%22Oid%22%3a%229e709c5c-68e4-40c1-afe4-86c0d9902689%22%7d Video Call Teams]<br />
<br />
<br />
<br />
== Welcome ==<br />
* Participants<br />
** Jacqueline Surugue<br />
** Leonidas Tzimis<br />
** Stephane Spahni<br />
** Marc Robberecht<br />
** Jose Costa Teixeira<br />
** Michael Tan (scribe)<br />
<br />
<br />
* Agenda approved<br />
* Agfa has sold the IT department to Dedalus.<br />
** This might be the last time Marc can join the IHE meeting.<br />
<br />
* No remarks on minutes previous [https://wiki.ihe.net/index.php/Pharm_Tech_Minutes_2020.02.27 meeting notes ]<br />
<br />
== F2F meetings ==<br />
* Porto F2F meeting is now postponed<br />
** Jose will be 25 on Sunday.<br />
* Joint Meeting IT. PCC. QRPH originally Franktfurt is now a virtual conference.<br />
** The meeting will be held during US office hours. Pharmacy will not join.<br />
<br />
* Chania F2F<br />
** It is currently difficult to plan. Everything is closed now. The nursing school might use the meeting rooms in the hospital.<br />
** Leonidas will search for alternative venue, for example the pharmacy wharehouse.<br />
** The government will make announcements beginning May and Leonidas will come back with news in May.<br />
<br />
== Documentation Publication topics ==<br />
* Publication discussions with Keith Boone and John Moerke. Keith has made an implementation guide for his own purpose. No decision has been made in the IHE group. Jose has continued to experiment with FHIR publishing on a HL7 site. Perhaps as IHE Pharmacy we should not wait and also go our own way.<br />
<br />
A motion is confirmed to let Jose put a trial publication on Github. Other members are requested to provide comments.<br />
<br />
== PrePresciption ==<br />
<br />
* Published in februari.<br />
<br />
== Supply ==<br />
<br />
* The action items are still to be followed up.<br />
* Jose will organize video conference calls<br />
* Michael can set up the video call meeting facilities.<br />
* Also invite external interested parties<br />
* Inquire GS1 for possible sponsoring.<br />
<br />
== Medication lists ==<br />
<br />
<br />
* Progress in Switzerland<br />
** Stephane will share the Concept medication plan:<br />
*** Concept: https://www.e-health-suisse.ch/fileadmin/user_upload/Dokumente/E/report-emedication-architecture-epr.pdf (english)<br />
*** Summary: https://www.e-health-suisse.ch/fileadmin/user_upload/Dokumente/E/report-emedication-architecture-epr-summary.pdf (english)<br />
** 8-12 communities will use the specifications which Stephane is writing.<br />
** Medication planning includes planning, prescribing and dispense.<br />
** It will make use of CDA and FHIR transactions<br />
** The FHIR version is written by Oliver Egger<br />
** Yearly national projectathons will include eMedication from September 2020 (3 required).<br />
** French speaking cantons expect to be live mid 2021.<br />
** Beside the corona crisis the Electronic identification of the all stakeholders causes delay.<br />
** Stephane will submit 2 change proposals for CMPD, of which one is for MHD. ( ITI 67).<br />
** Who manages the transaction numbers for PHARM? Mary Jungers<br />
<br />
* Jose will publish the medication list implementation guide.<br />
** Michael will set a doodle to discuss these topics.<br />
<br />
== Marcom ==<br />
<br />
* The European Connectathon has been moved to 2- 6 November.<br />
<br />
== Any other business ==<br />
<br />
* Jose has applied for a IHE Europe vendor co-chair, but application has been declined because there is no IHE Portugal as a member of IHE Europe. Jose could have applied through IHE Belgium.<br />
<br />
* The next call is planned for 28th of May.<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2020.01.23&diff=119657Pharm Tech Minutes 2020.01.232020-01-27T07:18:46Z<p>Stephane.spahni: /* Marcom */</p>
<hr />
<div>= Agenda =<br />
<br />
: Zoom link<br />
: https://zoom.us/j/6378337332?status=success<br />
<br />
<br />
<br />
== Welcome ==<br />
* Participants:<br />
** Stephane Spahni<br />
** Leonidas Tzimis<br />
** Michael Tan<br />
** Esther Peelen<br />
<br />
<br />
* Review and Approve Agenda<br />
* Review minutes previous meeting: <br />
<br />
https://wiki.ihe.net/index.php/Pharm_Tech_Minutes_2019.12.19<br />
No remarks. Approved by Stephane.<br />
<br />
== Brussels IHE World Summit ==<br />
* request from Juergen to spread the word around about the World Summit.<br />
* Intended attendance: Stephane , Esther, Juergen, Michael<br />
* Interesting program according to Esther. GS1 will also present.<br />
** There will be several opportunities for networking.<br />
***networking event of world summit on Tuesday,<br />
***IHE NL intending to organize event for NL participants on Wednesday.<br />
*** Networking event on Thursday for IHE connectathon.<br />
<br />
* marketing request<br />
** It has been mentioned in IHE NL bulletin, <br />
** Michael will broadcast during HL7 Netherlands ALF meeting<br />
** try social media.<br />
<br />
== Marcom ==<br />
* the white paper that won a price (Jacqueline).<br />
** Esther could not find the presentation of Jacqueline.<br />
** It is in French, Stephane has made a copy of the interview, which he will send to whole group.<br />
** It is free of copyright. Translate in English.<br />
** Suggestion for interview with Jacqueline and a link to her document. <br />
** Esther will ask Johanneke GS1 to do the interview.<br />
<br />
* the EAHP presentation in March (Leonidas),<br />
** 25,26,27 March theere are 5 seminars. Topic is Future of healthcare. <br />
** Leonidas will present, There are 20 slides about IHE. Also about EpSos, Antilope. <br />
** Leonidas prefers to publish afterwards. <br />
** Should we make a joint initiative EAHP, IHE, GS1, HL7?<br />
** Just inform HL7 Europe ( Chronaki) about the conference.<br />
<br />
== F2F Spring meeting ==<br />
* E-mail Sarah Bell: ITI, PCC, QRPH will meet in February in Chicago.<br />
* PHARM is not invited. So no one from PHARM will join in Chicago.<br />
<br />
<br />
* PHARM agrees that we must arrange the postponed F2F of Brussels.<br />
* We agree to focus on April? May is too late.<br />
* For Stephane 20,21,22 April is best.<br />
* Orthodox Easter is 19 April.<br />
<br />
* Michael will send a doodle poll to inquire about participation and dates<br />
* Main topics to discuss are Medication List and supply.<br />
* A logical place for the F2F would be near Switzerland, because of the National program of medication list. <br />
* It would also be beneficial to invite Oliver Egger to the F2F because of this topic.<br />
* See topic below on medication list.<br />
* Hotels are expensive in Geneva and Bern. We should consider renting a house under AirBnB and instead of hotel costs.<br />
* ( In the meantime Jose has invited us for Porto, also investigate this option)<br />
* Michael and Stephane will investigate possibilities.<br />
<br />
== PrePresciption ==<br />
<br />
* Publication of CMPD<br />
** Mary Jungers has sent 3 files.<br />
** Stephane will review tomorrow.<br />
** Expected publication next week.<br />
<br />
== Supply ==<br />
* It is not known if the Supply whitepaper is published.<br />
* Jose would set up a schedule for supply calls. But these calls have not been arranged.<br />
<br />
* Michael will discuss with Jose at HL7.<br />
<br />
== Medication lists ==<br />
<br />
* Progress in Switzerland<br />
** Final validation of Stephanes document planned for next week.<br />
** Currently working on medication services. This will part of the core platform. <br />
** Certification is required, but first 3 projectathons necessary. <br />
* First implementation at HCI ( distribution centre for Switzerland). <br />
* Many pharmacies belong to HCI. <br />
* Suggestion to arrange a visit at HCI and combine with F2F in April.<br />
* The company is near Bern.<br />
<br />
== Any other business ==<br />
<br />
* No other topics.<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Minutes]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2018.02.13&diff=107878Pharm Tech Minutes 2018.02.132018-03-05T15:17:53Z<p>Stephane.spahni: /* 13:45 - 15:15 Community Profiles */</p>
<hr />
<div>= Meeting Minutes =<br />
<br />
= Notes=<br />
<br />
== 09:00 - 11:45 Joint Meeting ITI, PCC, QRPH, PHARM ==<br />
<br />
* ITI, PCC, PHARM, QRPH round-table updates<br />
<br />
* PHARM FHIR profiles and roadmap<br />
** Current: MMA , UBP Profile<br />
** Upcoming: Supply of medication and devices, Adverse event reporting.<br />
<br />
* Joint work: Device implantation using IHE profiles<br />
* PCC is working together with HL7 ( Iona)<br />
<br />
* FHIR Roadmap and strategy - profiles and publication<br />
** ExampleScenario, IG Publisher<br />
** Join the workgroup on the documentation.<br />
<br />
== 12:30 - 13:45 --- Lunch --- ==<br />
<br />
== 13:45 - 15:15 Community Profiles ==<br />
<br />
* E-medication is based on clinical workflows.<br />
* E-prescriptions is focused on reimbursement of the prescription costs.<br />
* A prescription actually consists of 2 components:<br />
** a therapeutical element<br />
** a logistical element.<br />
* Medication list is based on the therapeutical elements.<br />
* Discussion of exceptional cases:<br />
** standard prescription process<br />
** home visit scenarios<br />
** blanc prescriptions where patient and medication is filled in.<br />
* Prescription ID is set immedicately on creation.<br />
* There must be always a medication line on a prescription.<br />
* Should we change the constraints on prescriptions? There are different options:<br />
** relax the constraints on e-prescriptions to deal with the exceptions.<br />
** call it a seperate document ( ordonance) do not regard it as a prescription.<br />
* Considers the legal impact on the possible options.<br />
* Recommendation to regard this as a seperate document.<br />
* We wait for the official Austrian requirements before we make a change.<br />
<br><br />
* There is a complaint about the use of namespaces. The name of the namespace was requested by Oliver Egger, but not done correctly.<br />
* The need of the namespace was because the HL7 CMET had to be adapted for Pharmacy needs.<br />
* The reason is that some software generation tools need to create their own alias. <br />
* Remove any constraints on the alias of the pharm.xml namespace in the prescription profile. The name can be chosen as wanted.<br />
* This would give issues on the transformation of stylesheets.<br />
* '''Stephane''' will ask Oliver Egger if is this is what he requested.<br />
<br />
* In Switzerland Geneva and Vaud have agreement on the implementing IHE Pharmacy profiles on an open source tool called "eHealth Connector" and ask vendors to use it to connect to HIE platform. It is intended to be used by hospitals, GP and pharmacies.<br />
<br />
== 15:15 - 16:45 Strategic approach on FHIR publication ==<br />
<br />
* Need to create awareness with the Board that decisions should be made on IHE method of FHIR publications. <br />
* HL7 is competing with workflows and connectathons and IHE is lagging behind.<br />
* Suggest to raise the topic in March at the IHE Board meeting in Las Vegas ( '''Juergen'''). Juergen needs a deck of 5 slides '''(Jose)''' to present, which he will present in the board. This should be a special topic for a retreat in The Hague. <br />
* Suggest to get the IHE board acquainted with the Furore ( Firely) to see if this company is willing to support IHE of using Simplifier. You need Simplifier as a registry for the FHIR community to find the IHE profiles.<br />
<br />
== 17:00 - Adjourn ==<br />
<br />
<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2017.06.15&diff=102162Pharm Tech Agenda 2017.06.152017-06-08T13:31:00Z<p>Stephane.spahni: /* 15:30 - 16:30 TO DO */</p>
<hr />
<div>= Meeting details =<br />
Thursday, 15th Juny 2017, 10:00-18:00 CET<br />
<br />
<br />
== '''Location''' ==<br />
<br />
Chania<br />
<br />
== '''WebEx details:''' ==<br />
<br />
<br />
=== '''Join IHE Pharmacy's WebEx meeting''' ===<br />
<br />
https://phastinternational.webex.com/join/ihepharmacy | <br />
or go to https://phastinternational.webex.com and paste 956 796 372<br />
<br />
=== Join by phone ===<br />
<br />
::* +33 17091 8646 France toll<br />
::* +43 125 302 1542 Austria toll<br />
::* +32 2894 8317 Belgium toll<br />
::* +41 43456 9564 Switzerland toll<br />
<br />
'''Others phone numbers :'''<br />
https://phastinternational.webex.com/cmp3100/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational&serviceType=MC&ED=329202667&tollFree=0<br />
<br />
Access code: 956 796 372<br />
<br />
= Agenda =<br />
<br />
<br />
== 09:00 - 10:00 Preparation, planning ==<br />
* Agenda, status of projects (MMA, Supply, ADM, Catalogs, MedDoc)<br />
* 30m Plan October meeting and if time allows, start drafting plan for 2018/19<br />
<br />
== 10:00 - 10:30 Pharmacy Board report review ==<br />
(Michael)<br />
<br />
== 10:30 - 12:30 MTP, PRE, DIS, PADV, PML change proposals ==<br />
(Stéphane)<br />
* Quick check if Publication/Ballot process is clear and ready<br />
<br />
== 12:30 - 13:30 Lunch ==<br />
<br />
== 13:30 - 15:00 Supply White paper ==<br />
<br />
== 15:00 - 15:30 Break ==<br />
<br />
== 15:30 - 16:30 Information about other workgroups ? ==<br />
(move from day 2)<br />
<br />
== 16:30 - 18:00 Visit to hospital ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2017.06.15&diff=102161Pharm Tech Agenda 2017.06.152017-06-08T13:29:39Z<p>Stephane.spahni: /* Agenda */</p>
<hr />
<div>= Meeting details =<br />
Thursday, 15th Juny 2017, 10:00-18:00 CET<br />
<br />
<br />
== '''Location''' ==<br />
<br />
Chania<br />
<br />
== '''WebEx details:''' ==<br />
<br />
<br />
=== '''Join IHE Pharmacy's WebEx meeting''' ===<br />
<br />
https://phastinternational.webex.com/join/ihepharmacy | <br />
or go to https://phastinternational.webex.com and paste 956 796 372<br />
<br />
=== Join by phone ===<br />
<br />
::* +33 17091 8646 France toll<br />
::* +43 125 302 1542 Austria toll<br />
::* +32 2894 8317 Belgium toll<br />
::* +41 43456 9564 Switzerland toll<br />
<br />
'''Others phone numbers :'''<br />
https://phastinternational.webex.com/cmp3100/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational&serviceType=MC&ED=329202667&tollFree=0<br />
<br />
Access code: 956 796 372<br />
<br />
= Agenda =<br />
<br />
<br />
== 09:00 - 10:00 Preparation, planning ==<br />
* Agenda, status of projects (MMA, Supply, ADM, Catalogs, MedDoc)<br />
* 30m Plan October meeting and if time allows, start drafting plan for 2018/19<br />
<br />
== 10:00 - 10:30 Pharmacy Board report review ==<br />
(Michael)<br />
<br />
== 10:30 - 12:30 MTP, PRE, DIS, PADV, PML change proposals ==<br />
(Stéphane)<br />
* Quick check if Publication/Ballot process is clear and ready<br />
<br />
== 12:30 - 13:30 Lunch ==<br />
<br />
== 13:30 - 15:00 Supply White paper ==<br />
<br />
== 15:00 - 15:30 Break ==<br />
<br />
== 15:30 - 16:30 TO DO ==<br />
<br />
== 16:30 - 18:00 Visit to hospital ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2016.03.24&diff=93469Pharm Tech Minutes 2016.03.242016-03-29T06:56:19Z<p>Stephane.spahni: /* Update on openMedicine */ Member of eHN expert groups, not eHN itself (Switzerland :-) )</p>
<hr />
<div>= Attendees =<br />
<br />
* Stéphane Spahni<br />
* José Costa Teixeira<br />
* Michael Tan<br />
<br />
== Review of Agenda ==<br />
Approved<br />
<br />
= Updates from work groups: =<br />
<br />
== Supply Discussions ==<br />
José states that the transactions have evolved a bit since the F2F meeting and are now more agreeable<br />
There is already a proposed implementation sequence, starting with the common and "easy" transactions like ordering, and then going to the more complicated ones like inventory/consumption.<br />
<br />
José will post this to the main mailing list and put on FTP<br />
<br />
Michael advises that FMD may provide a good boost for the Supply profiles. During the next supply call, Jose will contact GS1 people (Christian and Esther) to assist with the FMD cross-over to supply.<br />
FMD short guidance paper is being prepared. Last revision was by Christian Hay.<br />
<br />
<br />
== FHIR Discussions ==<br />
Jose sent a request to start with Administration. We agree that no reply from the group = no objection, so we should continue. <br />
<br />
Next step is to come up with a set of transactions and start profiling - as soon as we have a template.<br />
<br />
Jose reports that the IHE Documentation Group is working on profile templates and FHIR will be one of the targeted standards. Hopefully this will give us a starting template for Volume2 . But for Volume 1 we should not need this. <br />
<br />
Overview of the considered transactions. Will be sent to the main group.<br />
<br />
'''Action Item: José send initial transaction set to Pharmacy WG (after review from FHIR group)'''<br />
<br />
Michael advises to write use cases where the transactions are visible. This is accepted - we will identify use cases where the transactions are used, and also showing optional transactions.<br />
<br />
'''Action Item: Michael to start drafting some use cases.'''<br />
<br />
FHIR workflow discussions are going well, but not finished. Jose has a good feeling that the current resources may almost suffice for IHE needs.<br />
<br />
<br />
== Update on CP PHARM 101 ==<br />
CP was lost and not integrated. It is the description of MTP reference in PRE and DIS profiles.<br />
<br />
Stéphane will have a request for other changes, so this can be combined.<br />
<br />
'''Action Item: Stéphane will look at this and eventually start from the CP to make the changes in the TF.'''<br />
<br />
<br />
== HL7 WGM in May ==<br />
Given the lack of topics and the limited availability of participants, there seems to be a consensus to not do this meeting.<br />
'''IHE proposes to cancel this year's meeting.'''<br />
<br />
<br />
== Update on openMedicine ==<br />
Discussion on sending several complementary identifiers in a prescription.<br />
<br />
Another point of attention is the need for formulary data exchange across the many entities. Several systems use ASCII but IHE has done some analysis and could be interesting to capture it.<br />
<br />
IHE is maintaining the epSOS specs but on a separate track. <br />
<br />
Changes from openMedicine would go from epSOS EXPAND to relay to the CEF eHN CBEH... which would then proceed with the changes. They may or not be requested also to Pharmacy. <br />
<br />
Stéphane is member of eHN expert groups.<br />
<br />
== Modeling Pharmacy profiles with MDHT tool ==<br />
To use MDHT, there is a need to add a templateID to determine the content structure.<br />
<br />
e.g. in the DIS profile, the following could be added (line <templateID...:<br />
<br />
<entryRelationship typeCode='REFR'><br />
'''<templateID='OID for PHARM + SubID for content sections'/>'''<br />
<substanceAdministration classCode='SBADM' moodCode='INT'><br />
<id root=' ' extension=' '/> <!-- Medication Treatment Plan Item Id --><br />
<code code='MTPItem'<br />
codeSystem='1.3.6.1.4.1.19376.1.9.2.2' <br />
displayName=' Medication Treatment Plan Item' <br />
codeSystemName='IHE Pharmacy Item Type List'/><br />
<consumable><br />
<br />
'''Action Item: Stéphane to confer quickly with Kai cc this problem in ArtDecor, and then proceed with the planning of the changes'''<br />
To be checked with Juergen about impact on profiles and existing implementations.<br />
<br />
<br />
== Calendar for publication ==<br />
Jose will discuss with Mary the dates for publication given our delays and lack of templates<br />
<br />
<br />
== Any other business ==<br />
Michael suggests that we start drafting an agenda for Vienna during our ISO meeting in Amsterdam in May.</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.06.05&diff=86428Pharm Tech Agenda 2015.06.052015-06-05T07:08:41Z<p>Stephane.spahni: /* Review of CP documents */</p>
<hr />
<div>= Meeting details =<br />
Friday, 5 June 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m6043b6ebdc434e2583ed40d79550a268 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m6043b6ebdc434e2583ed40d79550a268]<br />
<br />
Meeting number: 951 235 855<br />
<br />
JOIN BY PHONE<br />
<br />
+33 17091 8646 France toll<br />
<br />
0800-9-19312 France toll free<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/phastinternational-en/globalcallin.php?serviceType=MC&ED=345860932&tollFree=1 Global Call-in numbers]<br />
<br />
Access code: 951 235 855<br />
<br />
== Agenda ==<br />
<br />
=== Review of CP documents ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment All Drafts are here]<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/Readme.txt Readme]<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-101v2.docx Definition of the MTP Item and introduction of the possibility for PRE and DIS items to reference a planning action (MTP Item)]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-102%20(includes%20PADV%20profile)%20v2.docx Introduction of MTP Items into the Pharmacy Pharmaceutical Advice (PADV) profile]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-103%20(includes%20CMPD%20profile)%20v2.docx Introduction of MTP Items into the Pharmacy Community Medication Prescription and Dispense (CMPD) profile]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-104%20(includes%20PML%20profile).docx Introduction of MTP Items into the Pharmacy Medication List (PML) profile]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/IHE_Pharmacy_Suppl_MTP_2015-05-27.docx MTP Profile]<br />
** Status:<br />
<br />
<br />
<br />
* Next steps<br />
<p>&nbsp;</p></div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.06.05&diff=86427Pharm Tech Agenda 2015.06.052015-06-05T07:06:02Z<p>Stephane.spahni: /* Review of CP documents */</p>
<hr />
<div>= Meeting details =<br />
Friday, 5 June 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m6043b6ebdc434e2583ed40d79550a268 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m6043b6ebdc434e2583ed40d79550a268]<br />
<br />
Meeting number: 951 235 855<br />
<br />
JOIN BY PHONE<br />
<br />
+33 17091 8646 France toll<br />
<br />
0800-9-19312 France toll free<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/phastinternational-en/globalcallin.php?serviceType=MC&ED=345860932&tollFree=1 Global Call-in numbers]<br />
<br />
Access code: 951 235 855<br />
<br />
== Agenda ==<br />
<br />
=== Review of CP documents ===<br />
[ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment All Drafts are here:]<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-101v2.docx Definition of the MTP Item and introduction of the possibility to PRE and DIS items to reference a planning action (MTP Item)]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-102%20(includes%20PADV%20profile)%20v2.docx Introduction of MTP Items into the Pharmacy Pharmaceutical Advice (PADV) profile]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-103%20(includes%20CMPD%20profile)%20v2.docx Introduction of MTP Items into the Pharmacy Community Medication Prescription and Dispense (CMPD) profile]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/CP-PHARM-104%20(includes%20PML%20profile).docx Introduction of MTP Items into the Pharmacy Medication List (PML) profile]<br />
** Status:<br />
<br />
<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/PRE%20Public%20Comment/IHE_Pharmacy_Suppl_MTP_2015-05-27.docx MTP Profile]<br />
** Status:<br />
<br />
<br />
<br />
* Next steps<br />
<p>&nbsp;</p></div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.04.28&diff=85376Pharm Tech Agenda 2015.04.282015-04-28T07:35:29Z<p>Stephane.spahni: /* Agenda */</p>
<hr />
<div>= Meeting details =<br />
Tuesday, 28 April 2015, 12:00 CEST (GMT+2)<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m7ff8e2acf59bdcd7cae7f4e6794c0110 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m7ff8e2acf59bdcd7cae7f4e6794c0110]<br />
<br />
Meeting number: 953 142 692<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of PADV Profile document ===<br />
<br />
* Review changes<br />
* Changed MTP Item: organizer or single element?<br />
* Reference to PRE Item: add the "code" element (optional) ?<br />
* Reference to DIS Item: add the "code" element (optional) ?<br />
<p>&nbsp;</p><br />
<br />
<br />
=== Review of CMPD Profile document ===<br />
<br />
* Notion of "current medication"<br />
* "Prescription Status"<br />
* Inclusion of MTP in each section<br />
* MTP-related transactions<br />
* Workflow<br />
<br />
<p>&nbsp;</p><br />
<br />
=== Review of last changes in MTP Profile document ===<br />
<p>&nbsp;</p></div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2015.03.11&diff=84386Pharm Tech Minutes 2015.03.112015-03-11T14:46:01Z<p>Stephane.spahni: /* Review of CMPD Profile document */</p>
<hr />
<div>=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
** Decision:<br />
*** One MTP Item per MTP Document<br />
*** MTP Definition = THE patient's plan<br />
*** Open issue: linking MTP Items together to reflect some relationships between them<br />
<br />
* Reported medications (page 16)<br />
** Decision: agreed on modified wording (MTP Item when HP endorses the medication) in order not to have conflict/duplicate with further Medication Statement<br />
<br />
* Next steps<br />
** Decision: Update according to discussed points above<br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
** Decision: to be discussed p2p Jürgen - Stéphane next week<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
** Decision: Jürgen working on a CP<br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]<br />
* Next steps:<br />
** Medication Treatment Placer is not mandatory - supported actors are described in concrete projects --> OK<br />
** Workflow: leave as they are, add a new section for explaining how the plan layer relates to existing workflow</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2015.03.11&diff=84385Pharm Tech Minutes 2015.03.112015-03-11T14:44:27Z<p>Stephane.spahni: /* Review of CPs */</p>
<hr />
<div>=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
** Decision:<br />
*** One MTP Item per MTP Document<br />
*** MTP Definition = THE patient's plan<br />
*** Open issue: linking MTP Items together to reflect some relationships between them<br />
<br />
* Reported medications (page 16)<br />
** Decision: agreed on modified wording (MTP Item when HP endorses the medication) in order not to have conflict/duplicate with further Medication Statement<br />
<br />
* Next steps<br />
** Decision: Update according to discussed points above<br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
** Decision: to be discussed p2p Jürgen - Stéphane next week<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
** Decision: Jürgen working on a CP<br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]<br />
* Next steps:<br />
** ...</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2015.03.11&diff=84384Pharm Tech Minutes 2015.03.112015-03-11T14:43:57Z<p>Stephane.spahni: /* Review of CPs */</p>
<hr />
<div>=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
** Decision:<br />
*** One MTP Item per MTP Document<br />
*** MTP Definition = THE patient's plan<br />
*** Open issue: linking MTP Items together to reflect some relationships between them<br />
<br />
* Reported medications (page 16)<br />
** Decision: agreed on modified wording (MTP Item when HP endorses the medication) in order not to have conflict/duplicate with further Medication Statement<br />
<br />
* Next steps<br />
** Decision: Update according to discussed points above<br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
** Decision:<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
** Decision: to be discussed p2p Jürgen - Stéphane next week<br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]<br />
* Next steps:<br />
** ...</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2015.03.11&diff=84383Pharm Tech Minutes 2015.03.112015-03-11T14:43:25Z<p>Stephane.spahni: /* Review of MTP Profile document */</p>
<hr />
<div>=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
** Decision:<br />
*** One MTP Item per MTP Document<br />
*** MTP Definition = THE patient's plan<br />
*** Open issue: linking MTP Items together to reflect some relationships between them<br />
<br />
* Reported medications (page 16)<br />
** Decision: agreed on modified wording (MTP Item when HP endorses the medication) in order not to have conflict/duplicate with further Medication Statement<br />
<br />
* Next steps<br />
** Decision: Update according to discussed points above<br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
** Decision:<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
** Decision:<br />
<p>&nbsp;</p><br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]<br />
* Next steps:<br />
** ...</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Minutes_2015.03.11&diff=84352Pharm Tech Minutes 2015.03.112015-03-10T15:22:43Z<p>Stephane.spahni: Created page with "=== Review of MTP Profile document === * [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx..."</p>
<hr />
<div>=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
** Decision:<br />
<br />
* Reported medications (page 16)<br />
** Decision:<br />
<br />
* Next steps<br />
** Decision:<br />
<p>&nbsp;</p><br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
** Decision:<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
** Decision:<br />
<p>&nbsp;</p><br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]<br />
* Next steps:<br />
** ...</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.03.11&diff=84349Pharm Tech Agenda 2015.03.112015-03-10T15:19:57Z<p>Stephane.spahni: /* Profile */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 11 March 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240]<br />
<br />
Meeting number: 959 390 393<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
<br />
* Reported medications (page 16)<br />
<br />
* Next steps<br />
<p>&nbsp;</p><br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
<p>&nbsp;</p><br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.03.11&diff=84348Pharm Tech Agenda 2015.03.112015-03-10T15:19:44Z<p>Stephane.spahni: /* Review of CMPD Profile document */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 11 March 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240]<br />
<br />
Meeting number: 959 390 393<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
<br />
* Reported medications (page 16)<br />
<br />
* Next steps<br />
<p>&nbsp;</p><br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
<p>&nbsp;</p><br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]<br />
<br />
== Profile ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.03.11&diff=84347Pharm Tech Agenda 2015.03.112015-03-10T15:19:18Z<p>Stephane.spahni: /* Review of CMPD Profile document */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 11 March 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240]<br />
<br />
Meeting number: 959 390 393<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
<br />
* Reported medications (page 16)<br />
<br />
* Next steps<br />
<p>&nbsp;</p><br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
<p>&nbsp;</p><br />
<br />
=== Review of CMPD Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx Draft here]<br />
*<br />
<br />
== Profile ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.03.11&diff=84346Pharm Tech Agenda 2015.03.112015-03-10T15:18:17Z<p>Stephane.spahni: /* Review of MTP Profile document */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 11 March 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240]<br />
<br />
Meeting number: 959 390 393<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
<br />
* Reported medications (page 16)<br />
<br />
* Next steps<br />
<p>&nbsp;</p><br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
<p>&nbsp;</p><br />
<br />
=== Review of CMPD Profile document ===<br />
:- Document [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx]<br />
:-<br />
<br />
== Profile ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.03.11&diff=84345Pharm Tech Agenda 2015.03.112015-03-10T15:17:41Z<p>Stephane.spahni: /* Review of CPs */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 11 March 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240]<br />
<br />
Meeting number: 959 390 393<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
:- <br />
<br />
* Reported medications (page 16)<br />
:-<br />
<br />
* Next steps<br />
:-<br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc Draft here]<br />
** Goal: distinguish between reference to PRE and reference to MTP (same content)<br />
<p>&nbsp;</p><br />
<br />
* CP mtp-pre-2: Reference to original CDA document (when in PML)<br />
** [ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc Draft here]<br />
** Goal: when included in a PML, preserve the fact that several PREs or MTPs are coming from the same CDA document<br />
** Useful also for DIS and PADV?<br />
<p>&nbsp;</p><br />
<br />
=== Review of CMPD Profile document ===<br />
:- Document [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx]<br />
:-<br />
<br />
== Profile ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.03.11&diff=84340Pharm Tech Agenda 2015.03.112015-03-10T15:09:42Z<p>Stephane.spahni: /* Review of MTP Profile document */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 11 March 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240]<br />
<br />
Meeting number: 959 390 393<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx Draft here]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
:- <br />
<br />
* Reported medications (page 16)<br />
:-<br />
<br />
* Next steps<br />
:-<br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
:- Document ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc<br />
:- <br />
<br />
* CP mtp-pre-2: Reference to CDA<br />
:- Document ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc<br />
:- <br />
<br />
=== Review of CMPD Profile document ===<br />
:- Document [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx]<br />
:-<br />
<br />
== Profile ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.03.11&diff=84336Pharm Tech Agenda 2015.03.112015-03-10T15:07:16Z<p>Stephane.spahni: /* Review of MTP Profile document */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 11 March 2015, 14:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=mc3a4a2d9926273a5d8c1b3d0570be240]<br />
<br />
Meeting number: 959 390 393<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* Document [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev04_2015-02-27.docx]<br />
<br />
* Glossary & definitions (pages 8, 10, 25)<br />
:- <br />
<br />
* Reported medications (page 16)<br />
:-<br />
<br />
* Next steps<br />
:-<br />
<br />
=== Review of CPs ===<br />
* CP mtp-pre-1: link PRE --> MTP & type of referenced content<br />
:- Document ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-1.doc<br />
:- <br />
<br />
* CP mtp-pre-2: Reference to CDA<br />
:- Document ftp://ftp.ihe.net/Pharmacy/TF_Maintenance-2015/CPs/Drafts/CP-PHARM-mtp-pre-2.doc<br />
:- <br />
<br />
=== Review of CMPD Profile document ===<br />
:- Document [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Pharmacy_Suppl_CMPD_Rev1.5_TI_2015-03-10.docx]<br />
:-<br />
<br />
== Profile ==</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.02.25&diff=83781Pharm Tech Agenda 2015.02.252015-02-23T07:36:02Z<p>Stephane.spahni: /* 13:00- 15:00 Medication Therapy Plan */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 25 February 2015, 9:00 CET<br />
<br />
Location : [https://goo.gl/maps/oxpwP Villa Modigliani] <br />
<br />
:*'''PHARMA : salon Nabis'''<br />
<br />
:*PCC : salon Baroques<br />
<br />
:*QRPH : salon Fauves-Expressionnistes<br />
<br />
:*ITI : salon Réalistes<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m4787c556bed03d822cac6b85e25b9f43 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m4787c556bed03d822cac6b85e25b9f43 ]<br />
<br />
Meeting number: 953 269 262<br />
<br />
JOIN BY PHONE<br />
<br />
+33 17091 8646 France toll<br />
<br />
0800-9-19312 France toll free<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/phastinternational-en/globalcallin.php?serviceType=MC&ED=324754042&tollFree=1 Global Call-in numbers]<br />
<br />
Access code: 953 269 262<br />
<br />
= Agenda =<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]<br />
<br />
=9:30-11:30 Joint Meeting ITI, PCC, QRPH=<br />
Joint PHARM/ITI/CC/QRPH<br />
<br />
Proposal From ITI:<br />
# PCC/QRPH/Pharmacy/ITI round-table report-out<br />
# De-ID Supplement Cross-committee discussion<br />
# XDS-CDR cross-committee issues<br />
# DAF Cross-committee issues<br />
# Profiling use of BPMN<br />
# Other topics TBD<br />
<br />
Proposal From Pharmacy:<br />
# Supply of Products for Healthcare <br />
## Method and status (10-20 minutes for open discussion on the approach to ensure traceability on the white papers)<br />
## Cross-domain supply (40+ minutes to look at the use cases, and discuss contribution from other domains.<br />
# Open discussion for advice on Formulary - What are the ITI solutions we could look at? SVS? Is this problem existing elsewhere?<br />
# PCC's DAF and Pharmacy's work item "Medication Data Collection"<br />
## Explanation of scope for Pharmacy work item<br />
## Use of DAF in gathering medication data<br />
# MHD and how to consider FHIR for CMPD and HMW<br />
<br />
=11:30- 12:00 Medication Management Concepts and Definitions=<br />
* Document "Medication Management Related Concepts and Definitions" (Michael/Stephen)<br />
* [[File:MedicationManagementConcepts.docx]]<br />
<br />
:* Word-Doc version (with comments of Leonidas)<br />
::* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Whitepapers/MedicationManagement/MedicationManagementRelatedConceptsandDefinitions_2014.10.02_LTz.docx ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Whitepapers/MedicationManagement/MedicationManagementRelatedConceptsandDefinitions_2014.10.02_LTz.docx]<br />
* Discussion<br />
:* Action item : ISO TC215<br />
* Defining next steps<br />
<br />
=12:00- 13:00 Lunch=<br />
<br />
=13:00- 15:00 Medication Therapy Plan=<br />
<br />
* Document "Medication Therapy Plan" [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev03_2015-02-02.docx ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev03_2015-02-02.docx]<br />
<br />
:* Discussion<br />
:* Next steps - diffusion for comments<br />
<br />
<br />
* Document "Workflow MTP - PRE - DIS - PADV" [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/workflow%20MTP%20-%20PRE%20-%20DIS%20-%20PADV%20-%20discussion.pptx ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/workflow%20MTP%20-%20PRE%20-%20DIS%20-%20PADV%20-%20discussion.pptx]<br />
:* Discussion<br />
:* PML/PRE profile: representation of the (paper) prescription (multiple prescriptions together on the same document)<br />
:* Next steps (CPs)<br />
<br />
==Medication Statements==<br />
<br />
==Medication Administration==<br />
<br />
=15:00 -15:15 Break=<br />
<br />
=15:15 - 16:30 Preparation of Joint ISO, HL7 and IHE meeting=<br />
<br />
=16:30 - 17:00 Preparation of F2F Chania=<br />
<br />
=17:00- 18:00 Action items=<br />
<br />
*Other remaing action items<br />
<br />
=18:00 Adjourn=<br />
<br />
[[Pharmacy Planning Committee]]<br />
<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.02.25&diff=83780Pharm Tech Agenda 2015.02.252015-02-23T07:32:41Z<p>Stephane.spahni: /* 13:00- 15:00 Medication Therapy Plan */</p>
<hr />
<div>= Meeting details =<br />
Wednesday, 25 February 2015, 9:00 CET<br />
<br />
Location : [https://goo.gl/maps/oxpwP Villa Modigliani] <br />
<br />
:*'''PHARMA : salon Nabis'''<br />
<br />
:*PCC : salon Baroques<br />
<br />
:*QRPH : salon Fauves-Expressionnistes<br />
<br />
:*ITI : salon Réalistes<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m4787c556bed03d822cac6b85e25b9f43 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m4787c556bed03d822cac6b85e25b9f43 ]<br />
<br />
Meeting number: 953 269 262<br />
<br />
JOIN BY PHONE<br />
<br />
+33 17091 8646 France toll<br />
<br />
0800-9-19312 France toll free<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/phastinternational-en/globalcallin.php?serviceType=MC&ED=324754042&tollFree=1 Global Call-in numbers]<br />
<br />
Access code: 953 269 262<br />
<br />
= Agenda =<br />
<br />
[[Pharmacy Technical Committee]]<br />
<br />
[[Category: Agenda]]<br />
<br />
=9:30-11:30 Joint Meeting ITI, PCC, QRPH=<br />
Joint PHARM/ITI/CC/QRPH<br />
<br />
Proposal From ITI:<br />
# PCC/QRPH/Pharmacy/ITI round-table report-out<br />
# De-ID Supplement Cross-committee discussion<br />
# XDS-CDR cross-committee issues<br />
# DAF Cross-committee issues<br />
# Profiling use of BPMN<br />
# Other topics TBD<br />
<br />
Proposal From Pharmacy:<br />
# Supply of Products for Healthcare <br />
## Method and status (10-20 minutes for open discussion on the approach to ensure traceability on the white papers)<br />
## Cross-domain supply (40+ minutes to look at the use cases, and discuss contribution from other domains.<br />
# Open discussion for advice on Formulary - What are the ITI solutions we could look at? SVS? Is this problem existing elsewhere?<br />
# PCC's DAF and Pharmacy's work item "Medication Data Collection"<br />
## Explanation of scope for Pharmacy work item<br />
## Use of DAF in gathering medication data<br />
# MHD and how to consider FHIR for CMPD and HMW<br />
<br />
=11:30- 12:00 Medication Management Concepts and Definitions=<br />
* Document "Medication Management Related Concepts and Definitions" (Michael/Stephen)<br />
* [[File:MedicationManagementConcepts.docx]]<br />
<br />
:* Word-Doc version (with comments of Leonidas)<br />
::* [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Whitepapers/MedicationManagement/MedicationManagementRelatedConceptsandDefinitions_2014.10.02_LTz.docx ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Whitepapers/MedicationManagement/MedicationManagementRelatedConceptsandDefinitions_2014.10.02_LTz.docx]<br />
* Discussion<br />
:* Action item : ISO TC215<br />
* Defining next steps<br />
<br />
=12:00- 13:00 Lunch=<br />
<br />
=13:00- 15:00 Medication Therapy Plan=<br />
<br />
* Document "Medication Therapy Plan" [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev03_2015-02-02.docx ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/IHE_Suppl_MTP_Rev03_2015-02-02.docx]<br />
<br />
:* Discussion<br />
:* Next steps - diffusion for comments<br />
<br />
<br />
* Document "Workflow MTP - PRE - DIS - PADV" [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/workflow%20MTP%20-%20PRE%20-%20DIS%20-%20PADV%20-%20discussion.pptx ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTreatmentPlan,%20MTP/workflow%20MTP%20-%20PRE%20-%20DIS%20-%20PADV%20-%20discussion.pptx]<br />
:* Discussion<br />
:* Next steps (CPs)<br />
<br />
==Medication Statements==<br />
<br />
==Medication Administration==<br />
<br />
=15:00 -15:15 Break=<br />
<br />
=15:15 - 16:30 Preparation of Joint ISO, HL7 and IHE meeting=<br />
<br />
=16:30 - 17:00 Preparation of F2F Chania=<br />
<br />
=17:00- 18:00 Action items=<br />
<br />
*Other remaing action items<br />
<br />
=18:00 Adjourn=<br />
<br />
[[Pharmacy Planning Committee]]<br />
<br />
<br />
[[Category: Agenda]]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.01.27&diff=83159Pharm Tech Agenda 2015.01.272015-01-26T08:55:00Z<p>Stephane.spahni: /* URL current version */</p>
<hr />
<div>= Meeting details =<br />
Tuesday, 27 January 2015, 08:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m535286e166f7aa894642c70236035d72 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m535286e166f7aa894642c70236035d72]<br />
<br />
Meeting number: 950 443 914<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* Section X Introduction (330)<br />
* Section X.4 MTP Overview (443)<br />
** Concepts<br />
** Use cases<br />
* Section 6 Document content<br />
** 6.3.3.10.S1.3 Prescriber (1259)<br />
** 6.3.4.E1.3.6 Lot number (1530)<br />
** 6.3.4.E1.3.8 Packaging (1541)<br />
** General policy: if a section is not used, shall we keep it for simplifying implementations or drop it ?<br />
* IDs<br />
** Template ID<br />
** Document code (LOINC)<br />
<br />
== Profile ==<br />
<br />
Medication Therapy Profile latest draft: [ftp://ftp.ihe.net/Pharmacy/yr6_2014-2015/Technical_Committee/Profiles/MedicationTherapy/IHE_Suppl_MTL_Rev02_2015-01-26.docx IHE_Suppl_MTL_Rev02_2015-01-26]</div>Stephane.spahnihttp://wiki.ihe.net/index.php?title=Pharm_Tech_Agenda_2015.01.27&diff=83158Pharm Tech Agenda 2015.01.272015-01-26T08:49:28Z<p>Stephane.spahni: /* Agenda */</p>
<hr />
<div>= Meeting details =<br />
Tuesday, 27 January 2015, 08:00 CET<br />
<br />
'''WebEx details:'''<br />
<br />
[https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m535286e166f7aa894642c70236035d72 https://phastinternational.webex.com/phastinternational-en/j.php?MTID=m535286e166f7aa894642c70236035d72]<br />
<br />
Meeting number: 950 443 914<br />
<br />
Call-in Numbers:<br />
[https://phastinternational.webex.com/cmp0401lsp11/webcomponents/widget/globalcallin/globalcallin.do?siteurl=phastinternational-en&serviceType=MC&eventID=329202682&tollFree=1 Global Call-in numbers]<br />
<br />
<br />
== Agenda ==<br />
<br />
=== Review of MTP Profile document ===<br />
* Section X Introduction (330)<br />
* Section X.4 MTP Overview (443)<br />
** Concepts<br />
** Use cases<br />
* Section 6 Document content<br />
** 6.3.3.10.S1.3 Prescriber (1259)<br />
** 6.3.4.E1.3.6 Lot number (1530)<br />
** 6.3.4.E1.3.8 Packaging (1541)<br />
** General policy: if a section is not used, shall we keep it for simplifying implementations or drop it ?<br />
* IDs<br />
** Template ID<br />
** Document code (LOINC)<br />
<br />
== Profile ==</div>Stephane.spahni